Business Description
Emergent BioSolutions Inc
NAICS : 325412
SIC : 2834
ISIN : US29089Q1058
Share Class Description:
EBS: Ordinary SharesTotal Employee Number:
900Compare
Compare
Traded in other countries / regions
EBS.USA0IGA.UKER4.Germany Index Membership
Russell 2000Russell 3000Russell 3000 IPO Date
2006-11-15Description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.28 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 1.1 | |||||
Debt-to-EBITDA | 3.75 | |||||
Interest Coverage | 1.31 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.23 | |||||
Beneish M-Score | -3.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.7 | |||||
3-Year Book Growth Rate | -28.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.8 | |||||
9-Day RSI | 46.47 | |||||
14-Day RSI | 47.55 | |||||
3-1 Month Momentum % | -5.92 | |||||
6-1 Month Momentum % | -38.66 | |||||
12-1 Month Momentum % | 8.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.29 | |||||
Quick Ratio | 2.08 | |||||
Cash Ratio | 1.08 | |||||
Days Inventory | 395.97 | |||||
Days Sales Outstanding | 60.43 | |||||
Days Payable | 64.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.3 | |||||
Shareholder Yield % | 30.55 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.04 | |||||
Operating Margin % | 11.29 | |||||
Net Margin % | -1.33 | |||||
EBITDA Margin % | 23.69 | |||||
FCF Margin % | 20.97 | |||||
OCF Margin % | 22.92 | |||||
ROE % | -1.58 | |||||
ROA % | -0.62 | |||||
3-Year ROIIC % | -11.41 | |||||
ROC (Joel Greenblatt) % | 10.64 | |||||
ROCE % | 4.7 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 8.61 | |||||
PE Ratio without NRI | 8.18 | |||||
Price-to-Owner-Earnings | 13.29 | |||||
PS Ratio | 0.74 | |||||
PB Ratio | 0.81 | |||||
Price-to-Tangible-Book | 8.02 | |||||
Price-to-Free-Cash-Flow | 3.32 | |||||
Price-to-Operating-Cash-Flow | 3.05 | |||||
EV-to-EBIT | 14.13 | |||||
EV-to-Forward-EBIT | 5.51 | |||||
EV-to-EBITDA | 5.46 | |||||
EV-to-Revenue | 1.29 | |||||
EV-to-Forward-Revenue | 1.16 | |||||
EV-to-FCF | 6.17 | |||||
Price-to-GF-Value | 1.73 | |||||
Price-to-Projected-FCF | 0.59 | |||||
Price-to-Median-PS-Value | 0.32 | |||||
Price-to-Graham-Number | 1.71 | |||||
Earnings Yield (Greenblatt) % | 7.08 | |||||
FCF Yield % | 32.08 | |||||
Forward Rate of Return (Yacktman) % | 38.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:EBS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Emergent BioSolutions Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 645.8 | ||
| EPS (TTM) ($) | -0.28 | ||
| Beta | 4.6083 | ||
| 3-Year Sharpe Ratio | 0.49 | ||
| 3-Year Sortino Ratio | 1.31 | ||
| Volatility % | 70.76 | ||
| 14-Day RSI | 47.55 | ||
| 14-Day ATR ($) | 0.394607 | ||
| 20-Day SMA ($) | 8.1945 | ||
| 12-1 Month Momentum % | 8.46 | ||
| 52-Week Range ($) | 5.615 - 14.06 | ||
| Shares Outstanding (Mil) | 51.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Emergent BioSolutions Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Emergent BioSolutions Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 17:00 | In 112 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 111 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 17:00 | In 28 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 27 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 14:00 | 8.07 (-3.70%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 13:20 | 8.21 (-2.49%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 17:00 | 7.99 (-2.32%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 7.99 (-2.32%) | ||
| General meeting for 2026 | 2026-04-27 09:00 | 8.03 (-0.37%) | ||
| Annual report for 2025 | 2026-02-27 | 11.10 (-0.72%) |
Show
Entries
Emergent BioSolutions Inc Frequently Asked Questions
What is Emergent BioSolutions Inc(EBS)'s stock price today?
The current price of EBS is $8.18. The 52 week high of EBS is $14.06 and 52 week low is $5.62.
When is next earnings date of Emergent BioSolutions Inc(EBS)?
The next earnings date of Emergent BioSolutions Inc(EBS) is 2026-08-06 Est..
Does Emergent BioSolutions Inc(EBS) pay dividends? If so, how much?
Emergent BioSolutions Inc(EBS) does not pay dividend.
Guru Commentaries on NYSE:EBS
No articles.
Press Release
Articles on Emergent BioSolutions Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers